The Zacks Analyst Blog Highlights Linde, Elevance Health, Lam Research, KLA and Johnson Controls
For Immediate Release
Chicago, IL – July 3, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Linde plc LIN, Elevance Health, Inc. ELV, Lam Research Corp. LRCX, KLA Corp. KLAC and Johnson Controls International plc JCI
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Linde, Elevance and Lam Research
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Linde plc, Elevance Health, Inc. and Lam Research Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Linde shares have outperformed the Zacks Chemical - Specialty industry over the past year (+34.9% vs. +16.2%) on the back of favorable underlying business momentum. The company's primary products in industrial gases include oxygen, which is used as life support in hospitals.
Linde has long-term contracts with on-site customers backed by minimum purchase requirements, thereby securing stable cashflows. In the profitable industrial gas market, the merger of Praxair and Linde has created an efficient player with considerable size advantages. For 2023, Linde increased adjusted EPS guidance representing 9%-13% year-over-year growth.
However, declining free cashflow is a concern, reflecting weakness in operating activities. Moreover, the company is extremely vulnerable to uncertainty associated with the slowdown of economic growth, as this could hurt demand for its industrial gases
(You can read the full research report on Linde here >>>)
Shares of Elevance Health have declined -9.4% over the past year against the Zacks Medical Services industry's decline of -14.3%. The company is witnessing escalating expenses which continue to put pressure on margins. Also, its declining cash flows can be concerning. ELV's balance sheet with a rising debt level can affect financial flexibility. As such, the stock warrants a cautious stance.
Nevertheless, Elevance Health's improving top line can be attributed to premium rate increases and higher memberships. We expect operating revenues to grow 5.4% year over year in 2023. Acquisitions and collaborations have enabled the company to strengthen its business portfolio.
Its well-performing Medicare and Medicaid businesses, coupled with several contract wins, are expected to drive its membership going ahead. The company's growing Carelon business is a major positive. ELV utilizes excess capital to boost shareholder value.
(You can read the full research report on Elevance Health here >>>)
Shares of Lam Research have outperformed the Zacks Semiconductor Equipment - Wafer Fabrication industry over the past six months (+53.3% vs. +41.0%). The company is benefiting from strength across systems business. Also, strengthening customer support business remains a major positive. Rising NAND requirement in accelerating 5G migration, video, and new game consoles is driving the top-line growth.
Strong momentum in the foundry and logic segment owing to the growing traction among etch and deposition technologies, is a major positive. Additionally, strength in both ALD metals and dielectrics deposition solutions is contributing well. Advanced packaging technology inflections are other positives.
However, growing supply chain constraints remain concerns. Imposition of export curbs on China's chip companies is a headwind. Also, cyclicality and adverse foreign currency fluctuations are overhangs.
(You can read the full research report on Lam Research here >>>)
Other noteworthy reports we are featuring today include KLA Corp. and Johnson Controls International plc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson Controls International plc (JCI) : Free Stock Analysis Report
KLA Corporation (KLAC) : Free Stock Analysis Report
Lam Research Corporation (LRCX) : Free Stock Analysis Report
Linde PLC (LIN) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
